Residual microvascular risk in diabetes: unmet needs and future directions.

Abstract

The burden of microvascular disease in patients with type 2 diabetes mellitus continues to escalate worldwide. Current standards of care reduce but do not eliminate the risk of diabetic retinopathy, nephropathy or neuropathy in these patients. Correction of atherogenic dyslipidemia, which is characterized by elevated triglyceride levels and low levels of HDL cholesterol, might provide additional benefit. Whereas promising data have been published with respect to fibrate therapy for maculopathy, fenofibrate for diabetic retinopathy, and statin or fibrate therapy for diabetic nephropathy, further studies are warranted to define optimal management strategies for reducing the residual microvascular risk. Such strategies are especially relevant in cases of diabetic peripheral neuropathy, where even optimal care fails to affect disease progression. Identification of those factors that are most relevant to residual diabetes-related microvascular risk is a priority of an ongoing multinational epidemiological study. In this Review, we highlight an urgent need to address the issue of microvascular residual risk in patients with or at risk of type 2 diabetes mellitus.

• Authors: Paola Fioretto, Paul M Dodson, Dan Ziegler, Robert S Rosenson
• Journal: Nature reviews. Endocrinology (Nat Rev Endocrinol) Vol. 6 Issue 1 Pg. 19-25 (Jan 2010) ISSN: 1759-5037 [Electronic] England
• PMID: 19859073 (Publication Type: Journal Article, Review)

Chemical References

• Blood Glucose
• Hypoglycemic Agents
• Lipids

Topics

• Animals
• Blood Glucose (metabolism)
• Capillaries (pathology)
• Coronary Angiography
• Diabetes Complications (pathology)
• Diabetes Mellitus, Type 2 (blood, drug therapy, therapy)
• Diabetic Angiopathies (blood, drug therapy, pathology, therapy)
• Humans
• Hypoglycemic Agents (administration & dosage, therapeutic use)
• Lipids (blood)